Buy Glenmark Pharmaceuticals; target of Rs 2300: Deven Choksey

Deven Choksey report on Glenmark Pharmaceuticals

Consolidated revenue rose sharply by 76.1% YoY (+85.2% QoQ) to INR 60,469 Mn, significantly above our estimates, driven by the one-time revenue recognition from the ISB-2001 upfront payment and steady performance across core markets. Base business recovery was offset by the GST-related one-time impact in India.

Outlook

We have rolled forward our valuation to Sept’27 estimates. We value Glenmark Pharma at 25.0x Sept’27 EPS implying a target price of INR 2,300. We reiterate our “BUY” rating on the stock.

For all recommendations report, click here